The New York Times looks at the growing number of biotech drugs that cost as much as $10,000 per month, often only prolonging patients' lives by a matter of weeks or months. For some cancer specialists, it seems only a matter of time before the use of the super-expensive drugs is rationed. And analysts note that pressure will grow as hundreds of late-stage biotech drugs are approved by the FDA.
- read this article from The New York Times for more